Cardiogenic shock
Conditions
Interventions
Ivabradine group:Ven-arterial extracorporeal membrane oxygenation(VA-ECMO) and ivabradine
Control group:VA-ECMO and placebo
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with acute and critical chest pain, with refractory cardiogenic shock or low cardiac output syndrome; 2. VA-ECMO supportive treatment is required; 3. Aged >= 18 years and = 80 beats/min; 5. Sign the informed consent form in person or by an entrusted agent; 6. Subjects who can take medication orally or receive nasal feeding medication; 7. Agree to collect clinical samples.
Exclusion criteria
Exclusion criteria: 1. Patients with respiratory failure requiring VV-ECMO supportive treatment; 2. Heparin-induced thrombocytopenia(HIT); 3. Irreversible serious central nervous system diseases such as brain herniation and flat brain waves; 4. Pregnant women; 5. Severe primary diseases that affect survival: multiple unresectable malignant tumors with metastases, hematological diseases, HIV, etc.; 6. History of allergy to the study drugs; 7. Those who have a serious condition and the expected survival time is less than 72 hours; 8. Patients who are deemed unsuitable for inclusion by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average length of stay in intensive care unit;Extracorporeal membrane oxygenation(ECMO) onboard duration; | — |
Countries
China
Contacts
Public ContactGuo Haipeng
Qilu Hospital of Shandong University
Outcome results
None listed